数据
资源
版本对比
免费注册
预约演示
免费注册
Mallinckrodt
Announces Board of Directors and Leadership Updates
2024-02-02
·
BioSpace
高管变更
生物类似药
Four Directors Added to Board Bring Seasoned Experience in Pharmaceuticals, Healthcare, Finance and Operations Paul Bisaro Returns as Board Chair Siggi Olafsson Will Continue as President, CEO and Board Member DUBLIN, Feb. 2, 2024 /PRNewswire/ -- Mallinckrodt Pharmaceuticals plc ("
Mallinckrodt
" or the "Company"), a global specialty pharmaceutical company, today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately. Mr. Bisaro has also been reappointed to his previous role as Board Chair. In addition, the Company announced that Siggi Olafsson has entered into a new employment agreement and will continue in his roles as
Mallinckrodt
's President and Chief Executive Officer and a member of the Board. Mr. Olafsson said, "The actions we took in 2023 have made
Mallinckrodt
a stronger company. As we move forward with renewed determination to help serve public health needs and deliver for our patients, we are thrilled to welcome back Paul as Board Chair. He brings deep familiarity with our business and our team, and we know we will benefit greatly from his insights. We are equally pleased about the appointments of Katina, Abbas and Wes. Our ability to attract these accomplished directors is a testament to what we have achieved so far and the opportunities ahead for
Mallinckrodt
." Select professional highlights of
Mallinckrodt
's new directors include: Paul Bisaro is a healthcare industry leader with more than three decades of leadership experience at generic and branded pharmaceutical companies. He served as
Mallinckrodt
's Board Chair from June 2022 to November 2023. Mr. Bisaro previously served as President, CEO and a director of
Impax Laboratories
, Executive Chairman of
Amneal Pharmaceuticals
, Executive Chairman of
Allergan
, President and CEO of
Actavis
(formerly
Watson Pharmaceuticals
), and President, Chief Operating Officer and a director of
Barr Pharmaceuticals
. Mr. Bisaro serves on the boards of
Zoetis
and
Myriad Genetics
and previously served on the boards of
TherapeuticsMD
and
Zimmer Biomet
. Katina Dorton has more than 20 years of finance and healthcare experience across fundraising, mergers and acquisitions, and business development, most recently serving as Chief Financial Officer of
NodThera
, a private biotechnology company. She previously served as CFO of
Repare Therapeutics
,
AVROBIO
and Inmatics and, earlier in her career, was a healthcare investment banker at
Morgan Stanley
and Needham. Ms. Dorton serves on the boards of
Fulcrum Therapeutics
and
TScan Therapeutics
and previously served on the boards of
Pandion Therapeutics
and US Ecology, among others. Abbas Hussain has more than 30 years of leadership and operating experience in healthcare, most recently serving as CEO of
Vifor
. He previously served as
GlaxoSmithKline
's Global President, Pharmaceuticals & Vaccines, and, earlier in his career, in various leadership roles at
Eli
Lilly and Company
. Mr. Hussain also has served on the boards of
Teva Pharmaceuticals
,
Aspen Pharmacare
,
Vifor
,
ViiV Healthcare
and
Cochlear
, among others. Wes Wheeler has more than 40 years of diversified leadership experience in healthcare, including business turnarounds and transformations, manufacturing, marketing, engineering, R&D and supply chain. He is currently a Pharmaceutical Services Consultant to KKR. He previously served as President of UPS Healthcare and its subsidiary Marken LLP, CEO, President and a director of
Patheon
(now a
Thermo Fisher Scientific
company), and President, R&D and Global Manufacturing at
Valeant Pharmaceuticals
. Earlier in his career, he held various leadership roles at
GlaxoSmithKline
and
ExxonMobil
in engineering, marketing and manufacturing. Mr. Bisaro said, "
Mallinckrodt
plays an important role addressing unmet patient needs and providing therapies with high clinical value. I am pleased to rejoin the Board and once again work alongside Siggi, the Executive Committee, as well as my colleagues on the Board of Directors, to continue this meaningful work and further improve execution and performance. We are all fully focused on unlocking
Mallinckrodt
's full potential and delivering benefits to patients, employees, shareholders and all other stakeholders." With the appointment of Messrs Bisaro, Hussain and Wheeler and Ms. Dorton,
Mallinckrodt
's Board comprises seven directors. In addition to Mr. Olafsson, the other incumbent directors are David Stetson and Jon Zinman, who were appointed in November 2023. About
Mallinckrodt
Mallinckrodt
is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segments' areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its
Specialty Generics
reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about
Mallinckrodt
, visit . CONTACTS Investor Relations Daniel Speciale Senior Vice President, Finance and CFO,
Specialty Generics
+1-314-654-3638 daniel.speciale@mnk.com Derek Belz Vice President, Investor Relations +1-314-654-3950 derek.belz@mnk.com Media Michael Freitag / Aaron Palash / Aura Reinhard / Catherine Simon Joele Frank, Wilkinson Brimmer Katcher +1-212-355-4449
Mallinckrodt
, the "M" brand mark and the
Mallinckrodt Pharmaceuticals
logo are trademarks of a
Mallinckrodt
company. Other brands are trademarks of a
Mallinckrodt
company or their respective owners. ©2024. Company Codes: NYSE:MNK, OTC-BB:MNKTQ, OTC-PINK:MNKTQ
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Mallinckrodt Plc
Impax Laboratories LLC
Amneal Pharmaceuticals, Inc.
[+29]
适应症
-
靶点
-
药物
-
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务